{"transactions":[{"id":2056252,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":120759,"kind":"person","name":"Chaya Moghrabi Dina","position":1,"cik":"0001822418","reported_name":"Chaya Moghrabi Dina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-11T16:13:25.000Z","date":"2023-01-11","kind":"disposition_to_issuer","acquired":false,"shares":11904,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the \"Merger\"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the \"Merger\"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option."}],"balance_after":0,"derivative":{"exercise_price":15.65,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":11904},"source":{"system":"sec-edgar","filing":"0000899243-23-001592","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623715/000089924323001592/doc4.xml","form_type":"4"}},{"id":2056251,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":120759,"kind":"person","name":"Chaya Moghrabi Dina","position":1,"cik":"0001822418","reported_name":"Chaya Moghrabi Dina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-11T16:13:25.000Z","date":"2023-01-11","kind":"disposition_to_issuer","acquired":false,"shares":23809,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the \"Merger\"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the \"Merger\"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-07-14","underlying":"Common Stock","underlying_shares":23809},"source":{"system":"sec-edgar","filing":"0000899243-23-001592","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623715/000089924323001592/doc4.xml","form_type":"4"}},{"id":2243695,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":120759,"kind":"person","name":"Chaya Moghrabi Dina","position":1,"cik":"0001822418","reported_name":"Chaya Moghrabi Dina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T16:40:27.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":11904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2023 of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":11904,"derivative":{"exercise_price":15.65,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":11904},"source":{"system":"sec-edgar","filing":"0001567619-22-012289","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623715/000156761922012289/doc1.xml","form_type":"4"}},{"id":2253525,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":120759,"kind":"person","name":"Chaya Moghrabi Dina","position":1,"cik":"0001822418","reported_name":"Chaya Moghrabi Dina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T20:09:35.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2023 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":22500,"derivative":{"exercise_price":1.32,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-22-032499","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919122032499/doc4.xml","form_type":"4"}},{"id":2630005,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":120759,"kind":"person","name":"Chaya Moghrabi Dina","position":1,"cik":"0001822418","reported_name":"Chaya Moghrabi Dina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-19T16:10:56.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":23809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth (1/36th) of the shares initially subject to the option will vest on each monthly anniversary measured from July 15, 2021 (the \"Vesting Commencement Date\"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":23809,"derivative":{"exercise_price":16,"expiration_date":"2031-07-14","underlying":"Common Stock","underlying_shares":23809},"source":{"system":"sec-edgar","filing":"0001567619-21-013641","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623715/000156761921013641/doc1.xml","form_type":"4"}},{"id":2700949,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":120759,"kind":"person","name":"Chaya Moghrabi Dina","position":1,"cik":"0001822418","reported_name":"Chaya Moghrabi Dina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-22T01:08:15.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2022 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":10000,"derivative":{"exercise_price":15.24,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-035148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919121035148/doc4.xml","form_type":"4"}},{"id":3005319,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":120759,"kind":"person","name":"Chaya Moghrabi Dina","position":1,"cik":"0001822418","reported_name":"Chaya Moghrabi Dina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-16T16:14:38.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":12500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 1,911,022 shares beneficially owned by Omega Fund VI, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a Director of the Issuer, is an advisor at Omega Fund Management, LLC, an entity affiliated with Omega Fund VI, L.P.\nand disclaims beneficial ownership of the shares held by Omega Fund VI, L.P., except to the extent of her pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1911022},"source":{"system":"sec-edgar","filing":"0001209191-20-055013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055013/doc4.xml","form_type":"4"}},{"id":3005318,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":120759,"kind":"person","name":"Chaya Moghrabi Dina","position":1,"cik":"0001822418","reported_name":"Chaya Moghrabi Dina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T16:14:38.000Z","date":"2020-10-14","kind":"purchase","acquired":true,"shares":250000,"price":15,"value":3750000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a Director of the Issuer, is an advisor at Omega Fund Management, LLC, an entity affiliated with Omega Fund VI, L.P.\nand disclaims beneficial ownership of the shares held by Omega Fund VI, L.P., except to the extent of her pecuniary interest therein."}],"balance_after":2161022,"source":{"system":"sec-edgar","filing":"0001209191-20-055013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055013/doc4.xml","form_type":"4"}},{"id":3005317,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":120759,"kind":"person","name":"Chaya Moghrabi Dina","position":1,"cik":"0001822418","reported_name":"Chaya Moghrabi Dina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T16:14:38.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":1911022,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 1,911,022 shares beneficially owned by Omega Fund VI, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a Director of the Issuer, is an advisor at Omega Fund Management, LLC, an entity affiliated with Omega Fund VI, L.P.\nand disclaims beneficial ownership of the shares held by Omega Fund VI, L.P., except to the extent of her pecuniary interest therein."}],"balance_after":1911022,"source":{"system":"sec-edgar","filing":"0001209191-20-055013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055013/doc4.xml","form_type":"4"}}]}